Hayden E. Klein

Updated guidelines include 13 recommendations and 52 practice points for clinicians treating patients with diabetes and chronic kidney disease (CKD).

A study showed 18.3% of adolescents with epilepsy (AWE) had at least 1 emotional or behavioral problem, and 24.9% of parents felt others had stigma towards their children with epilepsy.

A review showed lifestyle intervention was linked to a 24% reduction in type 2 diabetes (T2D) incidence among women with prior gestational diabetes, compared with standard of care.

A study showed that Canadian women living with HIV were less likely to get vitamin D through dairy consumption, but more likely to take vitamin D supplements, compared with women without HIV.

Patrick Reville, MD, MPH, instructor, Department of Leukemia, MD Anderson Cancer Center, explains the implications of the longer-term follow-up of venetoclax in combination with the chemotherapy regimen cladribine, high-dose cytarabine, idarubicin (CLIA) and how age is a factor when considering chemotherapy options.

Across several Institute for Value-Based Medicine® (IVBM) events held in 2022, the most-viewed content from these events cover a variety of topics in oncology care.

This year’s most-read type 1 diabetes (T1D) articles highlighted important trends, breakthrough technologies, and more major findings for patients with T1D.

Patrick Reville, MD, MPH, instructor, Department of Leukemia, MD Anderson Cancer Center, elaborates on how certain patients responded to the updated treatment regimen.

Of 6563 men who have sex with men (MSM) living in urban areas in 2017, only 7.7% reported HIV self-testing in the past year.

Cemiplimab with chemotherapy appears to offer value comparable to other options and may be "an important tool to use" in first-line treatment of non-small cell lung cancer (NSCLC), said Davey Daniel, MD, chief medical officer for OneOncology, lung cancer specialist.

The US Preventive Services Task Force (USPSTF) announced its recommendation for HIV pre-exposure prophylaxis (PrEP).

Tom Robinson, vice president of global access at JDRF, talks about how the community and people living with type 1 diabetes (T1D) have contributed to the T1D Index, from development to publication and going forward.

Patrick Reville, MD, MPH, instructor, Department of Leukemia, MD Anderson Cancer Center, discusses findings on an updated treatment regimen for newly-diagnosed acute myeloid leukemia and high-risk myelodysplastic syndrome.

The study also showed daily energy intake was inversely correlated with estimated glucose disposal rate (eGDR), a marker for insulin resistance (IR).

Leaders from Ochsner, Xavier, and their partners gathered on September 13, 2022, in New Orleans to offer an overview of the Healthy State initiative during a session of the Institute for Value-Based Medicine®.

This new study shows that family medicine physicians in rural areas tend to be less comfortable in HIV pre-exposure prophylaxis (PrEP)-related clinical activities and conversations with adolescents than those in urban areas.

Health care providers must acknowledge unconscious bias and watch for it to make sure treatments are given equitably, said Mary Cushman, MD, professor of medicine at the University of Vermont, director of the thrombosis and hemostasis program at the University of Vermont Medical Center.

The longer follow-up in the primary analysis of TRANSFORM provides confidence in the durability of patient responses to lisocabtagene maraleucel (liso-cel), said Jeremy Abramson, MD, director of the lymphoma program, Massachusetts General Hospital Cancer Center.

Ajai Chari, MD, professor of medicine, director of clinical research, Icahn School of Medicine at Mount Sinai, explains the mechanism of action of talquetamab and what method of delivery patients may prefer.

Third-line ponatinib is the optimal treatment option for patients with chronic myeloid leukemia in chronic phase (CML-CP) without T3151 mutation, said Elias Jabbour, MD, professor of medicine, Department of Leukemia, MD Anderson Cancer Center.

About 10% of patients with blood cancer, especially those with B-cell lymphomas, who did not make anti-spike antibodies after vaccination experienced breakthrough COVID-19 infection, said Lee Greenberger, PhD, chief scientific officer, Leukemia and Lymphoma Society.

Federico Stella, MD, University of Milan, explains why it was important to challenge the idea that the low-microbial protective diet is more beneficial than a nonrestrictive diet in patients with neutropenia.

Building equitable clinical trials means being thoughtful about trial design and criteria, said Matthew J. Maurer, DSc, statistician at Mayo Clinic, director of the statistics and informatics core of the Lymphoma Epidemiology of Outcomes (LEO) cohort.

The field of hemophilia therapy is advancing, with hemostatic rebalancing agents and gene therapy expected over the next year, said Steven W. Pipe, MD, a professor of pediatrics and pathology at the University of Michigan, Ann Arbor and medical director of the Pediatric Hemophilia and Coagulation Disorders Program and medical director of the Special Coagulation Laboratory.

Tom Robinson, vice president of global access at JDRF, lists 3 pieces of advice for groups looking to create indexes for other conditions similar to the Type 1 Diabetes (T1D) Index.

Due to the study’s small sample, further research is needed to understand the role of bromocriptine in reducing blood pressure and artery stiffness in youth with type 1 diabetes (T1D).

Emma Searle, PhD, consultant hematologist, The Christie Hospital NHS Foundation Trust, touches on key points learnt from MajesTEC-2 data and other data to look forward to at the 64th American Society of Hematology (ASH) Annual Meeting and Exposition.

Neil Iyengar, MD, from Memorial Sloan Kettering Cancer Center, is expecting updates on therapies to fight human epidermal growth factor 2 (HER2)–positive breast cancer and novel antibody drug conjugates at the upcoming San Antonio Breast Cancer Symposium (SABCS).

The first priority isn't limiting the rise in type 1 diabetes (T1D) prevalence, it's limiting the rise of missing prevalence, said Tom Robinson, vice president of global access at JDRF.

A review including nearly 40 million total participants showed a statistically significant positive association between infection with COVID-19 and risk of type 1 or type 2 diabetes.